Three vaccinated people acquired hepatitis B during a study of switching to long-acting injectable HIV treatment, a finding that highlights a blind spot in current monitoring guidelines, aidsmap reported from HIV Glasgow 2026.
The infections were asymptomatic and detected only through tests for hepatitis B core antibody and surface antibody.
Data from Spanish and Italian cohorts presented at the meeting showed that hepatitis B reactivation rates after moving to injectable cabotegravir/rilpivirine were low or non-existent. However, the Italian study highlighted the risk of poor or non-existent immunity to hepatitis B despite prior vaccination.
A narrative review published in 2026 examined the risk of occult hepatitis B infection (OBI) reactivation following switches to non-HBV-active antiretroviral therapy. The review defined OBI as the persistence of replication-competent hepatitis B virus DNA in the liver in the absence of detectable hepatitis B surface antigen (HBsAg).
It concluded that reactivation after withdrawal of HBV-active antiretrovirals in HBsAg-negative, anti-hepatitis B core antibody-positive people with HIV is a real but infrequent event.
Reactivation tends to concentrate in certain settings, including advanced or poorly controlled HIV infection, absence of protective anti-HBs antibodies, and a history of HBsAg loss during antiviral treatment. In contrast, individuals with sustained HIV virological suppression, preserved CD4+ cell counts, and markers of effective immune control face a low absolute risk of clinically significant reactivation.
The findings support a risk-based approach to antiretroviral simplification incorporating HBV serological history, vaccination status, and post-switch monitoring, rather than uniform restrictions on treatment switches in people with resolved HBV infection.